BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Canopus BioPharma, Inc. Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine


11/3/2008 6:31:44 AM

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC:CBIA - News); (www.canopusbiopharma.com) today announced that it has successfully completed the second phase of its cancer vaccine development.

The specialized laboratory study was analyzed at the Southern Research Institute in Birmingham, Alabama. The study used the blood of healthy human volunteers, vaccinated with Canopus Biopharma’s cancer vaccine peptides, which then demonstrated anti-cancer properties against a panel of 12 human cancer cell lines in tissue culture.

For the first time, successful human testing confirms that Canopus BioPharma’s proprietary, patented use of these cancer-targeted peptide antigens is effective as a vaccine against human cancer cells. When used as a vaccine in healthy volunteers, the peptide antigens generate antibodies that are non-toxic to normal cells, but significantly effective in destroying human cancer cells in-vitro. In effect, the peptide antigens work by stimulating a person’s own immune system, to protect the individual from developing certain forms of cancer.

“Successful results from this series of laboratory tests, using vaccinated, healthy volunteers, confirms proof of principle in humans,” said Elizabeth Shanahan-Prendergast, President of Oncology at Canopus BioPharma. “In the laboratory, the vaccinated human blood demonstrated that it can significantly inhibit the growth of a broad range of human cancer cells -- including colorectal, prostate, small-cell lung, pancreatic, ovarian and breast -- when compared to a control sample of non-vaccinated human blood.”

“Southern Research Institute is a recognized leader in scientific research, serving clients throughout the biotechnology industry, including the National Institutes of Health and the U.S. Environmental Protection Agency,” said Patrick T. Prendergast, Chairman and CEO, Canopus BioPharma. “According to Kalorama Information’s 2007 report, the cancer vaccine market will generate up to $700 million in potential new revenue this year and $8.4 billion by 2012. Now that we have proof of principle, in a human in-vivo study, we will be actively looking for a co-development partner to bring this novel vaccine to market as soon as possible.”

About Canopus BioPharma, Inc.

Canopus BioPharma, Inc. (OTC:CBIA - News) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods in the areas of infectious disease, radiation protection, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has, since 2001, been committed to becoming a market trend setter in a new era of healthcare. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, initially for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland, and the USA. Additional information on the company is available at www.canopusbiopharma.com.

Contact:

Media Contact: Edge Communications, Inc. Ken Greenberg, 818-990-5001 ken@edgecommunicationsinc.com or Canopus BioPharma Len Rothstein, President 818-980-5008 Fax: 818-980-5088 len@canopusbiopharma.com

Source: Canopus BioPharma, Inc.


Read at BioSpace.com


   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->